359 related articles for article (PubMed ID: 32361014)
1. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
Offin M; Shaverdian N; Rimner A; Lobaugh S; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Lee N; Kris MG; Rudin CM; Zhang Z; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Aug; 149():205-211. PubMed ID: 32361014
[TBL] [Abstract][Full Text] [Related]
2. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
Shaverdian N; Offin M; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Hellmann MD; Rimner A; Paik PK; Chaft JE; Gomez DR
J Thorac Oncol; 2021 Aug; 16(8):1392-1402. PubMed ID: 33992811
[TBL] [Abstract][Full Text] [Related]
4. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
[TBL] [Abstract][Full Text] [Related]
5. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
Verschueren MV; Dijs T; Gulikers JL; Veelen AV; Croes S; Hendriks LE; Smit AA; Bloem LT; Egberts AC; van de Garde EM; Peters BJ
Immunotherapy; 2023 Aug; 15(11):839-851. PubMed ID: 37291888
[TBL] [Abstract][Full Text] [Related]
8. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
[TBL] [Abstract][Full Text] [Related]
10. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
[TBL] [Abstract][Full Text] [Related]
12. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Paz-Ares L; Spira A; Raben D; Planchard D; Cho BC; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Spigel D; Senan S; Langer CJ; Perez BA; Boothman AM; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ; Faivre-Finn C
Ann Oncol; 2020 Jun; 31(6):798-806. PubMed ID: 32209338
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
[TBL] [Abstract][Full Text] [Related]
14. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
18. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
Faivre-Finn C; Vicente D; Kurata T; Planchard D; Paz-Ares L; Vansteenkiste JF; Spigel DR; Garassino MC; Reck M; Senan S; Naidoo J; Rimner A; Wu YL; Gray JE; Özgüroğlu M; Lee KH; Cho BC; Kato T; de Wit M; Newton M; Wang L; Thiyagarajah P; Antonia SJ
J Thorac Oncol; 2021 May; 16(5):860-867. PubMed ID: 33476803
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
